Response to Comments: MolDX: Next Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies

This document is a Response to Comments for MolDX Next Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies (LCD DL38504) and does not itself contain specific coverage criteria. For detailed indications, limitations, documentation requirements, and frequency limits, refer to LCD DL38504; the notice period began 12/26/2019 and the policy became effective 02/10/2020.